Policy Developments - Hainan Province has released a plan to enhance the quality of generic drugs, supporting the expedited registration and market entry of first generic products, particularly those that are urgently needed in clinics or have high prices or supply shortages [1] - The plan includes strengthening supervision of entrusted production and supporting consistency evaluations for the quality and efficacy of generic drugs, which will improve overall drug quality and ensure public safety [1] Drug and Device Approvals - Huasheng Technology's Sanqi Tongshu Capsules have been approved as the first secondary protected traditional Chinese medicine by the National Medical Products Administration, enhancing the company's core competitiveness in treating cardiovascular diseases [2] - United Imaging Healthcare's digital subtraction angiography system (DSA) uAngioAVIVA has received FDA approval, marking it as the first and only domestic DSA device allowed in the U.S. market [3] - Warner Pharmaceuticals has received a listing approval notice for potassium sulfate, which will enrich the company's product line and enhance its core competitiveness [4] - Xinhua Medical has obtained a Class II medical device registration certificate for its multi-chamber cleaning and disinfection device, which significantly reduces processing time compared to fully automatic devices [5] Financial Reports - Kelun Pharmaceutical reported a 29.42% year-on-year decline in revenue for Q1 2025, totaling 4.389 billion yuan, with a net profit decrease of 43.07% to 584 million yuan [6][7] - AstraZeneca's Q1 2025 revenue reached $13.588 billion, a 10% increase year-on-year, driven by double-digit growth in oncology and biopharmaceuticals [8] Capital Market Activities - Koser Medical Technology has completed nearly 100 million yuan in B+ round financing, which will be used for core product development and global market expansion [9] - Xellar Biosystems has secured several million yuan in strategic investment from XtalPi, aimed at accelerating the development of its organ-on-chip technology and expanding international collaborations [10] Industry Developments - Chen Yuqing has been appointed as the new chairman of Fosun Pharma, succeeding Wu Yifang, and will oversee the company's strategic development and organizational growth [11] - Merck has announced a $1 billion investment to build a production facility in Wilmington, Delaware, aimed at producing the next generation of biopharmaceuticals, including Keytruda [12] - Prilenia has entered a collaboration agreement with Ferrer for the oral sigma-1 receptor agonist Pridopidine, with a total deal value of up to €500 million [13] - Junshi Biosciences has signed a licensing agreement with Sandoz for its HLX13 monoclonal antibody, receiving an upfront payment of $31 million and potential milestone payments totaling $1.6 billion [14] Public Sentiment Alerts - Medici has announced that major shareholder Chen Jianhuang plans to reduce his stake by up to 2.23% between May 26 and August 25, 2025, due to personal funding needs [15]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd. * 於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 關連交易 設立目標基金 合夥協議的主要條款如下： 日期 設立目標基金 董事會欣然宣佈，於2025年4月29日，本公司之附屬公司蘇州君明與河南復健、豫健生物 及鄭州航空港資本簽訂合夥協議，據此，各方擬共同設立目標基金。目標基金計劃募集 資金為人民幣2,500百萬元，其中：蘇州君明（ 作為有限合夥人 ）擬以現金出資人民幣490 百 萬元 、 河 南復 健（ 作 為普 通 合 夥人 ）擬 以 現 金出 資 人 民幣 10 百萬 元 、 豫健 生 物（ 作為 有 限合夥人 ）擬以現金出資人民幣1,500百萬元及鄭州航空港資本（ 作為有限合夥人 ）擬以現 金出資人民幣500百萬元。目標基金 ...

Core Insights - Shanghai Fosun Pharmaceutical Group Co., Ltd. reported Q1 2025 revenue of 9.42 billion yuan and a net profit of 765 million yuan, with operating cash flow of 1.056 billion yuan [1] Group 1: Financial Performance - The company achieved a revenue of 9.42 billion yuan in Q1 2025 [1] - The net profit attributable to shareholders was 765 million yuan [1] - Operating cash flow for the quarter was 1.056 billion yuan [1] Group 2: Product Development and Approvals - The company has several innovative drug products progressing towards market launch, expected to enter a "growth phase" in 2025 [1] - In January 2025, the registration application for the innovative small molecule CDK4/6 inhibitor, Fovetisil Capsules, was accepted by the National Medical Products Administration [1] - In February 2025, the innovative drug Vantorel (Tianapano Tablets) was approved for treating CKD adult dialysis patients in China [1] - In March 2025, the listing application for the new drug Dihydrosuifinib Capsules was accepted by the National Medical Products Administration [1] - In March 2025, the innovative anti-HER2 monoclonal antibody HLX22 received orphan drug designation from the FDA for gastric cancer treatment [1] Group 3: International Expansion - The innovative anti-PD-1 monoclonal antibody, Surulitinib, has been approved in over 30 countries, including China, Europe, and Southeast Asia, benefiting more than 100,000 patients [2] - The subsidiary, Fosun Pharma, signed a licensing agreement with Dr. Reddy's, granting exclusive commercialization rights for the biosimilar HLX15 in the U.S. and 42 European countries [2] Group 4: Share Buyback - In Q1 2025, the company initiated a new round of share buybacks, purchasing 1.61 million A-shares for approximately 39.99 million yuan [2] - The company also repurchased 1.66 million H-shares for about 22.91 million Hong Kong dollars [2]

Financial Performance - The group's operating revenue for Q1 2025 was RMB 9,420,322,797.34, a decrease of 7.26% compared to RMB 10,157,255,262.40 in the same period last year[9]. - Net profit attributable to shareholders of the listed company increased by 25.42% to RMB 764,757,750.06 from RMB 609,733,627.26 year-on-year[9]. - Net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 32.56% to RMB 410,421,422.44 from RMB 608,535,465.59 year-on-year[9]. - The net cash flow from operating activities increased by 15.08% to RMB 1,055,679,878.45 compared to RMB 917,312,105.03 in the same period last year[9]. - Basic and diluted earnings per share were both RMB 0.29, representing a 26.09% increase from RMB 0.23 in the previous year[9]. - The weighted average return on equity increased by 0.28 percentage points to 1.61% from 1.33% year-on-year[9]. - Total revenue for Q1 2025 was approximately ¥9.42 billion, a decrease of 7.3% compared to ¥10.16 billion in Q1 2024[37]. - Operating profit for Q1 2025 increased to approximately ¥1.36 billion, up 33.1% from ¥1.02 billion in Q1 2024[37]. - Net profit for Q1 2025 reached approximately ¥941.57 million, representing a 19.8% increase from ¥786.22 million in Q1 2024[37]. - Investment income for Q1 2025 significantly rose to approximately ¥1.28 billion, compared to ¥335.56 million in Q1 2024[37]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 240,500[16]. - The largest shareholder, Shanghai Fosun High Technology (Group) Co., Ltd., holds 889,890,955 shares, representing 33.31% of the total shares[16]. - HKSCC Nominees Limited is the second-largest shareholder with 551,392,815 shares, accounting for 20.64%[16]. - The total shares held by the top 10 shareholders account for approximately 35.99% of the total shares outstanding, which is 2,671,326,465 shares[18]. - The company has a significant portion of shares pledged, with 708,300,000 shares under pledge by the largest shareholder[16]. - The top 10 unrestricted shareholders collectively hold 1,600,000,000 shares, indicating a strong base of support[17]. - The largest shareholder also holds 71,533,500 H shares, contributing to the overall shareholding structure[18]. - The company has a diverse shareholder base, with various investment funds holding significant stakes[16]. - There are no reported related party transactions among the top shareholders[17]. Operational Insights - The decrease in operating revenue was primarily due to the impact of centralized procurement policies for pharmaceuticals[9]. - The increase in net profit was mainly attributed to gains from the sale of shares in Unicorn II Holdings Limited and changes in the fair value of financial assets held by the group[9]. - The group achieved a revenue of RMB 9.42 billion in Q1 2025, a decrease compared to the same period last year[19]. - The net profit attributable to shareholders was RMB 765 million, with a net profit of RMB 410 million after deducting non-recurring gains and losses[19]. - The net cash flow from operating activities was RMB 1.056 billion, indicating ongoing efforts to optimize asset structure and accelerate cash flow[19]. Research and Development - The group received approval for two innovative drugs, including the anti-PD-1 monoclonal antibody, Surulimumab Injection, for the treatment of extensive-stage small cell lung cancer (ES-SCLC) in the EU[19]. - The group also obtained approval for the world's first phosphate absorption inhibitor, Tenapanor Hydrochloride Tablets, in China, providing more treatment options for patients with dialysis-related hyperphosphatemia[20]. - A licensing agreement was established with Dr. Reddy's Laboratories for the commercialization of HLX15, a biosimilar drug, in the US and 42 European countries[21]. - The group is focusing on optimizing R&D project management and resource allocation to enhance the efficiency of innovative product development[19]. - The group is actively pursuing internationalization strategies and strengthening global licensing collaborations[21]. - The group has multiple ongoing clinical trials, including HLX43 for advanced gastric cancer and XS-S003 for paroxysmal nocturnal hemoglobinuria[23][24]. Financial Strategy - The company approved a share repurchase plan for A-shares with a total amount not less than RMB 300 million and not exceeding RMB 600 million, with a maximum repurchase price of RMB 30 per share[25]. - As of the reporting period, the company has repurchased 1,613,300 A-shares, accounting for approximately 0.0604% of the total share capital, with a total repurchase amount of approximately RMB 39.99 million[25]. - The company approved a share repurchase plan for H-shares, allowing for the repurchase of up to 27,597,025 shares, which is 5% of the total H-shares as of June 26, 2024[26]. - As of the reporting period, the company has repurchased 1,655,500 H-shares, accounting for approximately 0.0620% of the total share capital, with a total repurchase amount of approximately HKD 22.91 million[27]. - The company registered medium-term notes and ultra-short-term financing bonds with amounts of RMB 4 billion and RMB 6 billion, respectively, valid for two years from March 20, 2025[28]. Asset and Liability Management - As of March 31, 2025, the company's total assets amounted to RMB 117.99 billion, an increase from RMB 117.46 billion as of December 31, 2024[31]. - The company's total liabilities as of March 31, 2025, were RMB 57.14 billion, a slight decrease from RMB 57.53 billion as of December 31, 2024[33]. - The company's cash and cash equivalents increased to RMB 13.72 billion as of March 31, 2025, compared to RMB 13.52 billion as of December 31, 2024[31]. - The company's inventory decreased to RMB 6.82 billion as of March 31, 2025, from RMB 7.26 billion as of December 31, 2024[31]. - The company's retained earnings increased to RMB 27.32 billion as of March 31, 2025, compared to RMB 26.55 billion as of December 31, 2024[33]. - The total equity as of March 31, 2025, was CNY 35,918,673,012.49, a slight increase from CNY 35,728,698,458.71 at the end of 2024[49].

Core Viewpoint - Fosun Pharma reported a decline in revenue but an increase in net profit for Q1 2025, attributed to asset sales and financial asset valuation changes [1][2]. Financial Performance - The company achieved operating revenue of 9.42 billion yuan, a year-on-year decrease of 7.26% [1]. - Net profit attributable to shareholders was 765 million yuan, a year-on-year increase of 25.42 [1]. - The non-recurring net profit was 410 million yuan, a year-on-year decrease of 32.56% [1]. - Net cash flow from operating activities was 1.056 billion yuan, a year-on-year increase of 15.08% [1]. Strategic Developments - Fosun Pharma is actively exiting and integrating non-core assets to optimize its asset structure and accelerate cash flow [2]. - The company received approvals for two innovative drugs during the reporting period: Hetronifly in the EU and a phosphate absorption inhibitor in China [2]. - Fosun Pharma strengthened global licensing collaborations, including agreements with Dr. Reddy's and Sandoz AG for commercialization rights in various regions [2]. Management Changes - The company announced a restructuring of its board, with key leadership changes including Chen Yuqing becoming the new chairman and executive director [3]. - The new leadership will focus on strategic development and talent management [3].

证券代码：600196 股票简称：复星医药 编号：临 2025-080 上海复星医药（集团）股份有限公司 关于董事分工调整及董事长变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，上海复星医药（集团）股份有限公司（以下简称"本公司"）董事会 收到吴以芳先生、王可心先生的书面辞职函，因工作安排调整，吴以芳先生、王 可心先生分别辞去本公司董事长、联席董事长职务。根据《上海复星医药（集团） 股份有限公司章程》（以下简称"《公司章程》"）规定，辞任自 2025 年 4 月 29 日生效。董事会对吴以芳先生、王可心先生担任本公司董事长、联席董事长期间 的工作表示感谢。 鉴于日后工作之安排，经本公司第九届董事会第七十八次会议审议批准，同 意吴以芳先生由执行董事改任非执行董事、王可心先生继续担任执行董事；同时， 同意陈玉卿先生由非执行董事改任执行董事，并选举陈玉卿先生担任第九届董事 会董事长、关晓晖女士担任第九届董事会联席董事长（不再担任副董事长）、文 德镛先生担任第九届董事会副董事长，上述任职变动均自 2025 年 4 月 ...

独立非执行董事候选人声明与承诺 （王全弟） 本人王全弟，已充分了解并同意由提名人上海复星医药（集团）股份有限公 司董事会提名为第十届董事会独立非执行董事候选人。本人公开声明，本人具备 独立非执行董事任职资格，保证不存在任何影响本人担任上海复星医药（集团） 股份有限公司独立非执行董事独立性的关系，具体声明并承诺如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、行政法规、部门规 章及其他规范性文件，具有 5 年以上法律、经济、会计、财务、管理或者其他履 行独立非执行董事职责所必需的工作经验。 本人已参加独立董事任职资格培训并取得相关证明材料。 二、本人任职资格符合下列法律、行政法规和部门规章的要求： （一）《中华人民共和国公司法》关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的规定（如适用）； （三）中国证监会《上市公司独立董事管理办法》、上海证券交易所自律监 管规则以及《上海复星医药（集团）股份有限公司公司章程》有关独立董事任职 资格和条件的相关规定； （四）中共中央纪委、中共中央组织部《关于规范中管干部辞去公职或者退 （离）休后担任上市公司、基金管理公司独立董事、独立监事 ...

证券代码：600196 股票简称：复星医药 编号：临 2025-083 上海复星医药（集团）股份有限公司 关于召开 2024 年度及 2025 年第一季度业绩说明会 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示（简称同正文） ●召开时间：2025 年 5 月 29 日(星期四)下午 15:30-17:00 ●召开方式：视频和网络互动 ●互动网址：上证路演中心（https://roadshow.sseinfo.com） ●投资者可于 2025 年 5 月 22 日(星期四)至 5 月 28 日(星期三)16:00 期间登录 上证路演中心网站首页点击"提问预征集"栏目进行提问，或将问题以电子邮件形 式发送至本公司投资者关系邮箱 ir@fosunpharma.com。本公司将于业绩说明会上就 投资者普遍关注的问题进行回答。 上海复星医药（集团）股份有限公司（以下简称"本公司"）于 2025 年 3 月 26 日披露 2024 年年度报告，并于 2025 年 4 月 30 日披露 2025 年第一季度报告。为了 ...

证券代码：600196 股票简称：复星医药 编号：临 2025-082 上海复星医药（集团）股份有限公司 关于参与设立私募股权投资基金暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 ●投资标的及金额： 控股企业苏州君明拟与河南复健、豫健生物、郑州航空港资本共同出资设立目 标基金，目标基金计划募集资金人民币 250,000 万元，其中：苏州君明（作为 LP） 拟现金出资人民币 49,000 万元认缴目标基金中的等值财产份额。目标基金设立后， 将成为本公司之合营公司。 ●由于河南复健（本公司之联营公司）纳入本公司控股股东复星高科技之合并 报表子公司范围、且本公司若干董事亦担任河南复健之 GP 的董事，根据上证所《上 市规则》，河南复健构成本公司的关联方、本次投资构成本公司的关联交易。 ●本次投资不构成《上市公司重大资产重组管理办法》规定的重大资产重组。 ●本次投资已经本公司第九届董事会第七十八次会议审议通过，无需提请股东 会批准。 ●特别风险提示： 1、截至本公告日期，目标基金尚处于筹备和募集阶段， ...

本人杨玉成，已充分了解并同意由提名人上海复星医药（集团）股份有限公 司董事会提名为第十届董事会独立非执行董事候选人。本人公开声明，本人具备 独立非执行董事任职资格，保证不存在任何影响本人担任上海复星医药（集团） 股份有限公司独立非执行董事独立性的关系，具体声明并承诺如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、行政法规、部门规 章及其他规范性文件，具有 5 年以上法律、经济、会计、财务、管理或者其他履 行独立非执行董事职责所必需的工作经验。 截至声明承诺日，本人尚未参加相关独立董事培训。本人承诺将于获提名后 尽快参加上海证券交易所举办的相关培训。 独立非执行董事候选人声明与承诺 （杨玉成） 二、本人任职资格符合下列法律、行政法规和部门规章的要求： （一）《中华人民共和国公司法》关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的规定（如适用）； （三）中国证监会《上市公司独立董事管理办法》、上海证券交易所自律监 管规则以及《上海复星医药（集团）股份有限公司公司章程》有关独立董事任职 资格和条件的相关规定； （四）中共中央纪委、中共中央组织部《关于规范中管干部辞去公职或者退 ...